Profile data is unavailable for this security.
About the company
RPG Life Sciences Limited is an India-based research-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations, and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has a presence in nephrology, oncology, rheumatology, cardiology, respiratory, pain management, vitamins & minerals, gastroenterology, and gynecology & pediatrics. The International Formulations business operates in the generics and branded generics space across Canada, Europe, Australia, New Zealand, and South America. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Quinfamide, Nicorandil, Haloperidol, Risperidone, Tolvaptan, Spironolactone, Sertraline, Naprosyn, Teristrong, and others.
- Revenue in INR (TTM)6.74bn
- Net income in INR2.03bn
- Incorporated2007
- Employees1.33k
- LocationRPG Life Sciences LtdRPG House463, Dr. Annie Besant Road, WorliMUMBAI 400030IndiaIND
- Phone+91 2 224981650
- Fax+91 2 224970127
- Websitehttps://www.rpglifesciences.com/website/index.php
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Panacea Biotec Ltd | 6.06bn | -77.80m | 21.24bn | 1.29k | -- | -- | 84.45 | 3.51 | -1.27 | -1.27 | 98.66 | -- | -- | -- | -- | 4,694,217.00 | -- | 13.08 | -- | 19.61 | 57.70 | 48.06 | -1.35 | 30.99 | -- | -11.50 | -- | 0.00 | -0.0132 | 0.5466 | -613.56 | -- | 48.74 | -- |
| Solara Active Pharma Sciences Ltd | 12.55bn | -191.10m | 21.64bn | 1.78k | -- | -- | 27.45 | 1.72 | -4.81 | -4.81 | 330.32 | -- | -- | -- | -- | 7,068,733.00 | -- | -3.27 | -- | -5.35 | 51.77 | 39.95 | -1.52 | -6.17 | -- | 0.7946 | -- | -- | -0.4003 | -0.5816 | 100.10 | -65.75 | -31.71 | -- |
| IOL Chemicals and Pharmaceuticals Ltd | 22.27bn | 1.16bn | 21.95bn | 2.89k | 18.93 | -- | 11.29 | 0.9853 | 3.95 | 3.95 | 75.87 | -- | -- | -- | -- | 7,704,566.00 | -- | 10.26 | -- | 13.42 | 34.42 | 32.57 | 5.20 | 9.33 | -- | 10.46 | -- | 13.68 | -2.51 | 1.88 | -24.82 | -22.49 | 21.61 | 5.92 |
| Bliss GVS Pharma Ltd | 8.68bn | 1.09bn | 23.48bn | 966.00 | 21.80 | -- | 15.95 | 2.70 | 10.18 | 10.18 | 80.97 | -- | -- | -- | -- | 8,986,598.00 | -- | 6.04 | -- | 7.54 | 52.65 | 46.33 | 13.18 | 9.45 | -- | 8.44 | -- | 8.27 | 5.13 | 3.27 | 11.72 | -2.82 | 5.18 | 0.00 |
| Hikal Ltd | 17.46bn | -130.00m | 25.85bn | 2.06k | -- | -- | 17.64 | 1.48 | -1.05 | -1.05 | 141.83 | -- | -- | -- | -- | 8,465,567.00 | -- | 4.78 | -- | 7.00 | 55.47 | 48.00 | -0.7447 | 5.71 | -- | 1.21 | -- | 14.83 | 4.21 | 4.29 | 30.46 | 1.46 | -2.77 | 3.13 |
| Unichem Laboratories Ltd | 22.14bn | 2.95bn | 25.89bn | 3.33k | 8.80 | -- | 6.18 | 1.17 | 41.79 | 41.79 | 314.32 | -- | -- | -- | -- | 6,654,374.00 | -- | -0.5598 | -- | -0.6977 | 54.06 | 55.09 | 13.32 | -1.18 | -- | 3.47 | -- | -- | 18.25 | 13.85 | 246.67 | -- | -18.68 | -- |
| Gufic BioSciences Ltd | 8.74bn | 569.19m | 29.38bn | 1.99k | 51.60 | 4.66 | 34.62 | 3.36 | 5.68 | 5.68 | 87.10 | 62.94 | 0.7354 | 1.87 | 2.75 | 4,394,322.00 | 4.79 | 10.27 | 7.34 | 16.11 | 55.47 | 46.41 | 6.52 | 10.48 | 1.06 | 3.13 | 0.3691 | 1.31 | 1.63 | 16.69 | -19.14 | 25.15 | 13.64 | 14.87 |
| Dishman Carbogen Amcis Ltd | 27.97bn | 1.19bn | 30.82bn | 1.11k | 25.96 | -- | 6.88 | 1.10 | 7.57 | 7.57 | 178.50 | -- | -- | -- | -- | 25,287,880.00 | -- | -0.7247 | -- | -0.9005 | 84.96 | 74.27 | 4.25 | -2.77 | -- | 1.31 | -- | -- | 3.66 | 5.82 | 102.11 | -54.07 | -11.91 | -- |
| SMS Pharmaceuticals Ltd | 8.97bn | 895.91m | 31.86bn | 1.47k | 33.59 | -- | 25.38 | 3.55 | 10.13 | 10.13 | 101.51 | -- | -- | -- | -- | 6,102,851.00 | -- | 5.58 | -- | 7.66 | 32.55 | 33.78 | 9.71 | 8.05 | -- | 5.85 | -- | 5.72 | 10.36 | 13.70 | 38.75 | 16.97 | 23.62 | 9.86 |
| RPG Life Sciences Ltd | 6.74bn | 2.03bn | 32.45bn | 1.33k | 16.02 | -- | 14.51 | 4.82 | 122.51 | 122.51 | 407.37 | -- | -- | -- | -- | 5,061,758.00 | -- | 21.05 | -- | 27.78 | 64.34 | 63.28 | 30.07 | 16.68 | -- | 174.47 | -- | 24.92 | 12.26 | 11.71 | 109.03 | 44.58 | 27.39 | 37.97 |
| Orchid Pharma Ltd | 8.11bn | 188.68m | 33.67bn | 737.00 | 178.55 | -- | 63.75 | 4.15 | 3.72 | 3.72 | 160.07 | -- | -- | -- | -- | 11,006,770.00 | -- | 1.40 | -- | 1.72 | 36.82 | 35.89 | 2.14 | 2.75 | -- | 0.4822 | -- | -- | 12.48 | 13.76 | 8.13 | -- | 104.06 | -- |
| Aarti Drugs Ltd | 25.22bn | 2.03bn | 33.94bn | 1.28k | 16.85 | -- | 12.75 | 1.35 | 22.07 | 22.07 | 274.99 | -- | -- | -- | -- | 19,639,960.00 | -- | 9.09 | -- | 14.39 | 36.35 | 22.09 | 8.03 | 8.08 | -- | 7.00 | -- | 6.07 | -5.60 | 5.74 | -1.90 | 3.53 | 29.85 | 14.87 |
| Gujarat Themis Biosyn Ltd | 1.59bn | 477.88m | 34.47bn | 221.00 | 72.13 | -- | 59.55 | 21.64 | 4.39 | 4.39 | 14.62 | -- | -- | -- | -- | 7,209,322.00 | -- | 30.70 | -- | 34.37 | 62.78 | 68.03 | 29.99 | 35.51 | -- | 55.73 | -- | -- | -11.20 | 12.12 | -17.56 | 15.55 | 104.61 | 24.95 |
| Senores Pharmaceuticals Ltd | 5.89bn | 1.02bn | 36.56bn | 194.00 | 35.42 | -- | 28.11 | 6.21 | 22.41 | 22.41 | 130.31 | -- | -- | -- | -- | 30,336,080.00 | -- | -- | -- | -- | 58.73 | -- | 17.48 | -- | -- | 5.94 | -- | -- | 85.64 | -- | 86.17 | -- | -- | -- |
| Innova Captab Ltd | 14.97bn | 1.32bn | 38.50bn | 1.95k | 29.08 | -- | 21.87 | 2.57 | 23.13 | 23.13 | 261.52 | -- | -- | -- | -- | 7,676,703.00 | -- | 10.02 | -- | 15.00 | 36.26 | 27.20 | 8.85 | 8.72 | -- | 12.45 | -- | -- | 15.02 | 27.21 | 35.95 | 35.69 | 109.94 | -- |
| Sun Pharma Advanced Research Co Ltd | 531.36m | -2.68bn | 43.39bn | 316.00 | -- | -- | -- | 81.65 | -8.26 | -8.26 | 1.64 | -- | -- | -- | -- | 1,681,519.00 | -- | -60.53 | -- | -129.98 | -4.34 | -3.83 | -504.20 | -168.34 | -- | -8.82 | -- | -- | -5.00 | -1.35 | 11.55 | -- | -28.16 | -- |
Data as of Feb 17 2026. Currency figures normalised to RPG Life Sciences Ltd's reporting currency: Indian Rupee INR
0.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Maybank Asset Management Sdn. Bhd.as of 31 Jul 2025 | 21.76k | 0.13% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 20.84k | 0.13% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 15.45k | 0.09% |
| Unifi Asset Management Pvt Ltd.as of 31 Dec 2025 | 6.57k | 0.04% |
| SSgA Funds Management, Inc.as of 05 Feb 2026 | 3.71k | 0.02% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 1.92k | 0.01% |
| Jennison Associates LLCas of 30 Sep 2025 | 1.05k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 137.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 53.00 | 0.00% |
| DFA Australia Ltd.as of 30 Nov 2025 | 35.00 | 0.00% |
More ▼
Data from 31 Aug 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
